Clinical trial progress of tremelimumab

Tremelimumab is a monoclonal antibody targeting CTLA-4. Its application in combination with durvalumab (PD-L1 inhibitor) in advanced hepatocellular carcinoma (HCC) is an important breakthrough in the field of immunotherapy in recent years. This combination solution was first developed by AstraZeneca and is branded Imjudo + Imfinzi. In the history of the development of tumor immunotherapy, the clinical trial results of temsitumumab indicate that CTLA-4 inhibitors have regained their clinical potential, especially in liver cancer, a cancer that is traditionally difficult to control with immunotherapy.

The most representative clinical study of temsitumumab is the HIMALAYA Phase III global multi-center randomized controlled study, which is a key study to evaluate the efficacy and safety of Imjudo + Imfinzi combination therapy and Sorafenib monotherapy. The study, which included adults with unresectable hepatocellular carcinoma, showed that compared with sorafenib, patients who received a single dose of temsilimumab plus continuous treatment with durvalumab had a significantly lower risk of death by 22%. More importantly, the three-year survival rate was 31%, compared with 20% in the control group, indicating that this immune dual-drug combination can not only bring longer survival, but may also delay the progression of the disease. The research results have been published, further enhancing the influence of temsitumumab in the international field of tumor immunity.

In terms of therapeutic mechanism, temsitumumab blocks the CTLA-4 pathway to relieve the "brake" effect of the immune system and enhance the ability of T cells to attack tumor cells. AndDurvalumab prevents tumors from evading immune surveillance by blockingPD-L1/PD-1 interaction. The combination of the two is called the "STRIDE regimen", which stands for "Single temsitumumab combined with durvalumab treatment (Single temsitumumab Regular Interval durvalumab ) ". This innovative immune combination program can activate a strong anti-tumor immune response at an early stage while maintaining long-term immune memory, resulting in a more lasting anti-cancer effect.

Judging from the FDA approval path, temsilimumab + durvalumab regimen is in It will be approved for first-line treatment of unresectable hepatocellular carcinoma (uHCC) in 2022, becoming another important option after sorafenib. This is also the first officially approved combination regimen of CTLA-4 inhibitors in the field of liver cancer, which means that immunotherapy has entered a new stage of "synergistic enhancement" from "single drug exploration". In addition to liver cancer, the research scope of temsitumumab has also expanded to non-small cell lung cancer (NSCLC) and other solid tumors. Multiple phase II and phase III trials are currently underway to further evaluate its long-term efficacy and tolerability.

In terms of safety, clinical studies show that the side effects of temsitumumab combination therapy are generally controllable and are mainly related to immunity, such as rash, fatigue, elevated liver enzymes, etc. Most of them can be alleviated through the intervention of hormones or immunomodulatory drugs. Since this drug acts on the early regulatory stage of the immune system, patients need to be regularly monitored for immune-related adverse events by experienced doctors during treatment.

Overall, the clinical trial progress of temsitumumab marks an important milestone in the treatment landscape of immunotherapy combination therapy for liver cancer. From laboratory research to clinical verification to FDA approval, its efficacy data and long-term survival benefits have allowed the global medical community to see the huge potential of immune synergistic therapy. In the future, with the release of more clinical trial results, temsitumumab is expected to become a core component of the treatment of various solid tumors and also open up a new direction for precision immunotherapy.

Reference: https://www.drugs.com/mtm/tremelimumab.html